type 2 diabetes and in those who were overweight or had obesity. The FDA recognized that the study had limitations, yet it raised enough concern to justify a deeper evaluation across the entire drug class.

To gain a broader view, the agency carried out a meta-analysis of 126 randomized controlled trials covering GLP-1 RA development programs. This large dataset included more than 134,000 patients and close to 289,000 person-years of exposure. Within that extensive pool, the FDA identified 15 probable NAION events. Ten occurred in patients treated with